Search - tctmd.com

Displaying 21 - 40 of 89

Sort: Relevancy | Date

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

News Daily News TCT 2019

BLADE-PCI: Antirestenotic Drug Flops in Diabetics, but Inflammation Hypothesis Lives On

October 02, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

September 29, 2019

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

September 24, 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

August 28, 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

News Conference News ESC 2018

GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI

Michael O'Riordan

August 27, 2018

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

News Daily News

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

August 17, 2018

TCTMD’s Top 10 Most Popular Stories for December 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

December 28, 2017

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

News Daily News

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

December 20, 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

News Conference News AHA 2017

Aspirin Protective Against Early Death/MI in Prior PCI Patients Undergoing Noncardiac Surgery

November 14, 2017

Generic ARBs Linked to Increased Adverse Events

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

TCTMD’s Top 10 Most Popular Stories for May 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

June 01, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.